About Us

Lotus is an emerging Chinese leader in offering medicines to ensure well-being, cure disease and improve quality of life. Our goal is to discover, develop and successfully market innovative products to help people globally, to help patients manage afflictions and to enhance the quality of life. We also seek to provide a return to shareholders that reflects our performance and to adequately reward those who invest ideas and resources in our company.

Lotus continues to discover, develop and successfully market innovative products to help people globally, to help patients manage afflictions and to enhance the quality of life. Lotus has a unique positioning amongst major pharmaceutical companies in China, as it resides in a small class of leadership in both patented and generic pharmaceuticals. The Company is strengthening its medicine-based portfolio, and investing in strategic growth platforms as follows:

Innovation-driven prescription medicines
Cost-effective and high-quality generic medicines
Retail Sales of leading self-medication (OTC) brands
Human vaccines that address public health and therapeutic needs

Lotus leads the regional industry with 14 new product approvals in the China since 2000, with key approvals in 2005. Lotus will make VALSARTAN the number one prescribed brand in its class of high blood pressure medications in China. Lotus owns and operates 10 retail outlets throughout metropolitan Beijing.

This website contains forward-looking statements that involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the company's business and financial results is included in the Company's filings, available via the United States Securities & Exchange Commission. Occasionally, the Company may select and post articles or opinions of third parties, with no known connection with the Company. These are considered expert or qualified writers about the Chinese economy and its various opportunities and pitfalls. The Company neither endorses nor rejects these views or content, and the articles are offered only for the readers' edification and personal analyses.